• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Analyzing Global Cord Blood's Short Interest

    9/23/22 2:12:46 PM ET
    $CO
    Managed Health Care
    Health Care
    Get the next $CO alert in real time by email

    Global Cord Blood's (NYSE:CO) short percent of float has risen 5.26% since its last report. The company recently reported that it has 205 thousand shares sold short, which is 0.4% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.3 days to cover their short positions on average.

    Why Short Interest Matters

    Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.

    Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.

    See Also: List of the most shorted stocks

    Global Cord Blood Short Interest Graph (3 Months)

    short_fig

    As you can see from the chart above the percentage of shares that are sold short for Global Cord Blood has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.

    Comparing Global Cord Blood's Short Interest Against Its Peers

    Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.

    According to Benzinga Pro, Global Cord Blood's peer group average for short interest as a percentage of float is 4.56%, which means the company has less short interest than most of its peers.

    Did you know that increasing short interest can actually be bullish for a stock? This post by Benzinga Money explains how you can profit from it..

    This article was generated by Benzinga's automated content engine and was reviewed by an editor.

    Get the next $CO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CO
    SEC Filings

    View All

    SEC Form 6-K filed by Global Cord Blood Corporation

    6-K - Global Cord Blood Corp (0001467808) (Filer)

    2/12/24 5:06:46 PM ET
    $CO
    Managed Health Care
    Health Care

    SEC Form 6-K filed by Global Cord Blood Corporation

    6-K - Global Cord Blood Corp (0001467808) (Filer)

    12/4/23 5:15:19 PM ET
    $CO
    Managed Health Care
    Health Care

    SEC Form 6-K filed by Global Cord Blood Corporation

    6-K - Global Cord Blood Corp (0001467808) (Filer)

    9/29/23 4:33:27 PM ET
    $CO
    Managed Health Care
    Health Care

    $CO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GLOBAL CORD BLOOD CORPORATION ANNOUNCES FAILURE TO FILE INTERIM FINANCIALS

    GEORGE TOWN, Cayman Islands and HONG KONG, April 13, 2023 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) (the "Company"), a provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services in China, announced that it received a notice (the "Notice") on April 3, 2023 from the New York Stock Exchange ("NYSE") with respect to its failure to timely file on Form 6-K its semi-annual financials for the six-month period ended September 30, 2022 (the "Interim Financials") as required by NYSE Listing Standard 203.03. As previously announced, on September 22, 2022, the Grand Court of the Cayman Islands issued an order (the "Order") appoi

    4/13/23 3:08:00 PM ET
    $CO
    Managed Health Care
    Health Care

    Global Cord Blood Corporation Announces Appointment of Joint Provisional Liquidators by The Grand Court Of The Cayman Islands

    Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that an order was made by the Grand Court of the Cayman Islands ("Grand Court") on September 22, 2022 (the "Order") appointing Margot MacInnis and John Royle of Grant Thornton Specialist Services (Cayman) Limited and Chow Tsz Nga Georgia of Grant Thornton Recovery & Reorganisation Limited as the Joint Provisional Liquidators of the Company (the "Joint Provisional Liquidators"). Upon the making of the Order, the powers of the directors of the Company are suspended. Blue Oce

    9/26/22 4:07:00 PM ET
    $CO
    Managed Health Care
    Health Care

    The Grand Court of the Cayman Islands Granted Blue Ocean's Application to Appoint Joint Provisional Liquidators for Global Cord Blood Corporation

    Blue Ocean Structure Investment Company Ltd., ("Blue Ocean") a significant shareholder of Global Cord Blood Corporation (the "Company" or "Global Cord") (NYSE:CO), today announced the Grand Court of the Cayman Islands (the "Court") issued an order granting the appointment of joint provisional liquidators ("JPLs") for Global Cord, pursuant to section 104(2) of the Companies Act (2022 Revision) (the "Companies Act"), upon the application filed by Blue Ocean dated 22 August 2022. Margot MacInnis and John Royle of Grant Thornton Specialist Services (Cayman) Limited, 2nd Floor, Century Yard, Cricket Square, Grand Cayman KY1-1102, Cayman Islands and Chow Tsz Nga Georgia have been appointed as JP

    9/23/22 1:52:00 PM ET
    $CO
    Managed Health Care
    Health Care

    $CO
    Leadership Updates

    Live Leadership Updates

    View All

    Global Cord Blood Corporation Announces Appointment of Joint Provisional Liquidators by The Grand Court Of The Cayman Islands

    Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that an order was made by the Grand Court of the Cayman Islands ("Grand Court") on September 22, 2022 (the "Order") appointing Margot MacInnis and John Royle of Grant Thornton Specialist Services (Cayman) Limited and Chow Tsz Nga Georgia of Grant Thornton Recovery & Reorganisation Limited as the Joint Provisional Liquidators of the Company (the "Joint Provisional Liquidators"). Upon the making of the Order, the powers of the directors of the Company are suspended. Blue Oce

    9/26/22 4:07:00 PM ET
    $CO
    Managed Health Care
    Health Care

    The Grand Court of the Cayman Islands Granted Blue Ocean's Application to Appoint Joint Provisional Liquidators for Global Cord Blood Corporation

    Blue Ocean Structure Investment Company Ltd., ("Blue Ocean") a significant shareholder of Global Cord Blood Corporation (the "Company" or "Global Cord") (NYSE:CO), today announced the Grand Court of the Cayman Islands (the "Court") issued an order granting the appointment of joint provisional liquidators ("JPLs") for Global Cord, pursuant to section 104(2) of the Companies Act (2022 Revision) (the "Companies Act"), upon the application filed by Blue Ocean dated 22 August 2022. Margot MacInnis and John Royle of Grant Thornton Specialist Services (Cayman) Limited, 2nd Floor, Century Yard, Cricket Square, Grand Cayman KY1-1102, Cayman Islands and Chow Tsz Nga Georgia have been appointed as JP

    9/23/22 1:52:00 PM ET
    $CO
    Managed Health Care
    Health Care

    Global Cord Blood Corporation Announces Results of 2021 Annual General Meeting

    HONG KONG, Dec. 7, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced the results of its 2021 Annual General Meeting of shareholders, held on December 7, 2021, in Hong Kong S.A.R., China. At the Annual General Meeting, the Company's shareholders ratified the re-appointment of KPMG Huazhen LLP as independent auditors of the Company for the financial year ending March 31, 2022, and authorized any duly formed committee of the directors to fix the remuneration of the independent auditors; and re-elected Ms.

    12/7/21 8:32:00 AM ET
    $CO
    Managed Health Care
    Health Care

    $CO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Global Cord Blood Corporation (Amendment)

    SC 13G/A - Global Cord Blood Corp (0001467808) (Subject)

    2/14/24 10:15:21 AM ET
    $CO
    Managed Health Care
    Health Care

    SEC Form SC 13G filed by Global Cord Blood Corporation

    SC 13G - Global Cord Blood Corp (0001467808) (Subject)

    2/14/23 10:23:43 AM ET
    $CO
    Managed Health Care
    Health Care

    SEC Form SC 13G/A filed by Global Cord Blood Corporation (Amendment)

    SC 13G/A - Global Cord Blood Corp (0001467808) (Subject)

    2/3/23 2:38:38 PM ET
    $CO
    Managed Health Care
    Health Care

    $CO
    Financials

    Live finance-specific insights

    View All

    Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2022

    Added 16,423 New Subscribers in 4QFY22 4QFY22 Revenues Down 1.7% YoY to RMB297.2 Million ($46.9 Million) 4QFY22 Gross Profit Down 0.5% YoY to RMB255.2 Million ($40.3 Million) 4QFY22 Operating Income Down 4.1% YoY to RMB142.1 Million ($22.4 Million) 4QFY22 Non-GAAP Operating Income Down 4.1% YoY to RMB153.9 Million ($24.3 Million) HONG KONG, July 5, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the fourth quarter and full year of fiscal 2022, ended March 31, 2022.

    7/5/22 4:16:00 PM ET
    $CO
    $INCY
    Managed Health Care
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch

    Global Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2022

    Added 18,985 New Subscribers in 3Q22Revenues Up 9.1% YoY to RMB317.2 Million ($49.8 Million)         Gross Profit Up 9.8% YoY to RMB269.9 Million ($42.4 Million)Operating Income Up 20.8% YoY to RMB149.7 Million ($23.5 Million) Non-GAAP Operating Income Up 18.6% YoY to RMB161.6 Million ($25.4 Million)Conference Call to be Held on March 1, 2022, at 8:00 a.m. ET HONG KONG, Feb. 28, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the third quarter and first nine month

    2/28/22 4:16:00 PM ET
    $CO
    Managed Health Care
    Health Care

    Global Cord Blood Corporation to Report Third Quarter and First Nine Months Fiscal 2022 Financial Results

    HONG KONG, Feb. 23, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that it plans to release its financial results for the third quarter and first nine months of fiscal 2022 on Monday, February 28, 2022, after the U.S. market close.  The Company will host a conference call at 8:00 a.m. ET on Tuesday, March 1, 2022 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question-and-answer session. Interested parties can access the audio webcast through

    2/23/22 7:00:00 AM ET
    $CO
    Managed Health Care
    Health Care